ABVC BioPharma, Inc.
corporate_fare Company Profile
ABVC BioPharma, Inc. (NASDAQ:ABVC) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 16 items for ABVC at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-10, rated 7/10. Across its 16 most recent items scored 7 or higher, the top rating is 9/10, with 10 rated 8 or above. Recent SEC coverage for ABVC spans S-3/A, 10-Q, 8-K, DEF 14A.
Recent high-impact activity:
- ABVC Amends $100M Shelf Registration While Cash Stands at $11,294
- ABVC Q3 10-Q: $11,294 Cash, $5.79M Working Capital Deficit, Going-Concern Doubt
- ABVC Closes $3.39M Discounted Convertible Note Deal and Settles Lind Litigation for $625,000
- ABVC Closes $3.39M OID Note Sale With 15% Conversion Discount and $625K Settlement Payout
- ABVC Sets October 28 Vote on 5.2M-Share Equity Plan and Related-Party Land Deal
Financial Snapshot
Short Interest & Short Volume
19.90 days to coverFINRA reported short interest of 602,938 shares in ABVC as of the October 30, 2026 settlement, a 2.2% increase from the prior period — about 19.9 days to cover at its recent average daily volume. On November 20, 2026, 22.1% of ABVC volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Moderate riskFiling-implied dilution signals for ABVC, detected from its recent SEC filings · based on capital-structure filings through 2026-11-13.
Prospectus Supplement Incorporates Q3 10-Q · Going-Concern and Liquidity Unchanged
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →